The joint positioning was carried out by the Federation of the European Pharmaceutical Industry (Efpia), to which Farmaindustria belongs, and eight other industry associations, including the World Association (Ifpma), the United States Association (PhRMA) and the United Kingdom Association, signed (APBI) “celebrated” The document was signed at the Climate Summit (COP28) to address climate change as an urgent health challenge.
The document emphasizes that pharmaceutical companies are leading the way in reducing emissions targets To do this, they invest in research and development with the aim of offering more sustainable products, manufacturing processes and supply chains from an environmental perspective.
In fact, eight out of ten major pharmaceutical companies worldwide have signed net zero or neutral emissions commitments in the short term, according to APBI. In Spain there are many large companies that are pursuing neutral or zero-emission goals in the coming years, some have already set targets for 2030.
Also at this COP 28, the Climate and Health Declaration was signed, with the aim of accelerating action to protect the health of the population from climate impacts. 123 countries have signed this declaration, including Spain, This represents a milestone in the recognition that governments need to prepare their health systems for the impacts of climate changeincluding increases in infectious diseases or air pollution.
The innovative pharmaceutical industry sees To achieve these goals, coordination between industry, governments and healthcare systems is essential in a highly regulated sector. “Investment in science and research and coordinated global collaboration will be critical to meeting our shared climate commitments and those set out at COP 28,” the positioning concludes.
In Spain, in addition to the above-mentioned commitments, and worldwide, the production facilities of medicines for human use already consume 70% of energy from renewable sources. In addition, waste generation has been reduced by up to 15% in the last three years.